氯吡格雷药物基因组学临床决策支持的实施:先发性结果返回项目经验
本文描述了在大型医疗系统先发性药物基因组学项目中,实施和迭代CYP2C19基因型指导的氯吡格雷药物基因组学临床决策支持工具的经验。多学科团队实施了自动化中断式警示,当生物库参与者存在CYP2C19中间或慢代谢型基因组指标时,在开具或续配氯吡格雷时触发。实施从狭窄的心血管适应症和场景开始,随后在四个主要维度上扩展,并基于不断演变的临床证据迭代方法。
要点
- CYP2C19中间或慢代谢型患者使用氯吡格雷增加动脉粥样硬化血栓事件风险。
- CDS警示从心血管适应症起步,逐步扩展至多地点、多场景和多提供者组。
- 多学科协作和临床医生接受度是扩展药物基因组学警示的关键促进因素。
核心结论
- 推荐多学科协作以促进心血管和脑血管疾病患者中使用CYP2C19基因型指导的抗血小板治疗。
- 不断演变的氯吡格雷药物基因组学证据需要 thoughtful 迭代实施工作和策略以优化长期维护和可持续性。
研究设计与样本
- 描述在大型医疗系统先发性药物基因组学项目中实施和迭代CYP2C19基因型指导的氯吡格雷CDS工具的经验。
主要发现
- 实施了自动化中断式警示,当生物库参与者存在结构化CYP2C19中间或慢代谢型基因组指标时,在开具或续配氯吡格雷时触发。
- 实施从狭窄的心血管适应症和场景开始,随后在四个主要维度上扩展:临床适应症、医疗系统地点可用性、护理场所(如住院与门诊)、提供者组(如心脏病学和神经病学)。
- 基于不断演变的临床证据和主动策略迭代方法以优化CDS维护和可持续性。
- 扩展的关键促进因素是在学术医疗中心社区中社会化更广泛的药物基因组学倡议,以及临床医生在实践中接受药物遗传学警示。
临床怎么用
- 对于心血管和脑血管疾病患者,可基于CYP2C19基因型指导氯吡格雷的使用。
- 实施CDS时建议多学科协作,并随着证据演变迭代实施策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe our experiences implementing and iterating CYP2C19 genotype-guided clopidogrel pharmacogenetic clinical decision support (CDS) tools over time in the setting of a large health system-wide, preemptive pharmacogenomics program. SUMMARY: Clopidogrel-treated patients who are genetically predicted cytochrome P450 isozyme 2C19 (CYP2C19) intermediate or poor metabolizers have an increased risk of atherothrombotic events, some of which can be life-threatening. The Clinical Pharmacogenetics Implementation Consortium provides guidance for the use of clopidogrel based on CYP2C19 genotype in patients with cardiovascular and cerebrovascular diseases. Our multidisciplinary team implemented an automated, interruptive alert that fires when clopidogrel is ordered or refilled for biobank participants with structured CYP2C19 intermediate or poor metabolizer genomic indicators in the electronic health record. The implementation began with a narrow cardiovascular indication and setting and was then scaled in 4 primary dimensions: (1) clinical indication; (2) availability across health-system locations; (3) care venue (e.g., inpatient vs outpatient); and (4) provider groups (eg, cardiology and neurology). We iterated our approach over time based on evolving clinical evidence and proactive strategies to optimize CDS maintenance and sustainability. A key facilitator of expansion was socialization of the broader pharmacogenomics initiative among our academic medical center community, accompanied by clinician acceptance of pharmacogenetic alerts in practice. CONCLUSION: A multidisciplinary collaboration is recommended to facilitate the use of CYP2C19 genotype-guided antiplatelet therapy in patients with cardiovascular and cerebrovascular diseases. Evolving clopidogrel pharmacogenetic evidence necessitates thoughtful iteration of implementation efforts and strategies to optimize long-term maintenance and sustainability.
引用
- Aquilante CL, Trinkley KE, Lee YM, et al. Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program. Am J Health Syst Pharm. 2024. PMID: 38253063. doi:10.1093/ajhp/zxae008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。